Last reviewed · How we verify
NCT07002346: INVIGORATE
INVIGORATE: A Study of QL1706 and Bevacizumab in Advanced First-Line Ovarian Clear Cell Carcinoma
Phase 3 trial testing QL1706 (bispecific antibody targeting PD-1 and CLTA-4) in Ovarian Clear Cell Carcinoma in 226 participants. Not yet recruiting.
1 June 2027
Quick facts
| Lead sponsor | Tongji Hospital |
|---|---|
| Phase | Phase 3 |
| Status | Not yet recruiting |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 226 |
| Start date | 1 June 2025 |
| Primary completion | 1 June 2027 |
| Estimated completion | 1 June 2029 |
| Sites | 1 location across China |
Drugs / interventions tested
- QL1706 (bispecific antibody targeting PD-1 and CLTA-4)
- Bevacizumab (Bevacizumab-Bvzr) — full drug profile →
- carboplatin (Carboplatin) — full drug profile →
- Paclitaxel — full drug profile →
Conditions studied
- Ovarian Clear Cell Carcinoma — all drugs for Ovarian Clear Cell Carcinoma →
Sponsor
Tongji Hospital
Who can join
Adults 18 to 75, female only, with Ovarian Clear Cell Carcinoma. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The goal of this clinical trial is to learn if QL1706 combined with bevacizumab can effectively treat adult female patients (18 to \<75 years old) with newly diagnosed FIGO stage IC-IV advanced ovarian clear cell carcinoma. The main questions it aims to answer are: 1. Does QL1706 combined with bevacizumab, compared to platinum-based chemotherapy, prolong patients' progression-free survival (PFS)? 2. What is the safety profile of QL1706 combined with bevacizumab, such as what medical problems (adverse events) do participants experience? Researchers will compare QL1706 combined with bevacizumab (experimental arm) to a standard chemotherapy regimen of paclitaxel plus carboplatin (control arm) to see if QL1706 combined with bevacizumab is more effective in the first-line treatment of advanced ovarian clear cell carcinoma. Participants will: 1. Be randomly assigned to receive either QL1706 combined with bevacizumab (QL1706 administered every 3 weeks, bevacizumab administered every 3 weeks) or paclitaxel plus carboplatin chemotherapy (administered every 3 weeks). 2. Visit the research center regularly for drug infusions, medical examinations (such as vital signs, physical exams, laboratory tests), and tumor imaging assessments. 3. Complete quality of life questionnaires as required.
Publications & conference data
2 peer-reviewed publications reference this trial (live from Europe PMC):
-
Advancements in the utilization of immune checkpoint inhibitors for the treatment of gynecological tumors.
Su Z, Zhang X, Xu J, Shen Y. · · 2026 · PMID 41983132 · DOI 10.3389/fimmu.2026.1686568 -
Advances in PD-1 and CTLA-4 dual-target immunotherapy for ovarian cancer.
Li DM, Pei KG, Yu XZ, Qie MR, et al · · 2025 · PMID 41256843 · DOI 10.3389/fimmu.2025.1686532
Verify or expand the search:
- PubMed search for NCT07002346
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of QL1706 (bispecific antibody targeting PD-1 and CLTA-4)
Trials testing the same drug.
- NCT07416058 — PHOENIX: QL1706 Plus Chemotherapy and Bevacizumab in AGA-Resistant, PD-L1 ≥50% Non-Squamous NSCLC · Phase 2 · not yet recruiting
- NCT07178171 — A Study of QL1706 Combined With Short-Cycle Anthracyclines or Taxanes for the Treatment of Early-Stage TNBC · Phase 1 · recruiting
- NCT07141186 — QL1706 in Patients With Recurrent and Metastatic Cervical Cancer Resistant to Prior PD-1/PD-L1 Antibody Therapy · Phase 2 · not yet recruiting
- NCT06939855 — QL1706 in the Treatment of Advanced Bone and Soft Tissue Sarcoma · Phase 2 · recruiting
- NCT07070700 — Cryoablation Combined With Lenvatinib Plus QL1706 (Iparomlimab/Tuvonralimab) in Patients With Advanced Intrahepatic Chol · Phase 2 · recruiting
Other recruiting trials for Ovarian Clear Cell Carcinoma
Currently open trials in the same condition.
- NCT06065462 — Safety and Efficacy of Targeting PP2A in Ovarian Clear Cell Carcinoma Using Dostarlimab and LB-100 · Phase 1, PHASE2 · recruiting
- NCT06279104 — A Comparative Study of the Treatment of Real-world Patients With Clear Cell Carcinoma of the Ovary · recruiting
- NCT05296512 — Pembrolizumab and Lenvatinib in Clear Cell Ovarian Cancer · Phase 2 · active not recruiting
- NCT04104776 — A Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and Lymphomas · Phase 1, PHASE2 · recruiting
Other Tongji Hospital trials
Trials by the same sponsor.
- NCT07537946 — Local Consolidation After Sintilimab Plus Lenvatinib for Metastatic Liver Cancer · Phase 3 · not yet recruiting
- NCT07537972 — Denosumab Strategy for Liver Cancer With Bone Metastases · Phase 2 · not yet recruiting
- NCT07537959 — Surgery Plus Systemic Therapy for Liver Cancer With Extrahepatic Metastases · NA · not yet recruiting
- NCT07527260 — Effects of Adenoidectomy on Symptoms and IgE Levels in Children With AR · NA · not yet recruiting
- NCT07524712 — Effects of Energy Versus Mechanical Surgical Devices on Postoperative Cough · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT07002346 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Tongji Hospital
- Last refreshed: 3 June 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07002346.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing